Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412

Richard M. Stone, Daniel J. DeAngelo, Virginia Klimek, Ilene Galinsky, Eli Estey, Stephen D Nimer, Wilson Grandin, David Lebwohl, Yanfeng Wang, Pamela Cohen, Edward A. Fox, Donna Neuberg, Jennifer Clark, D. Gary Gilliland, James D. Griffin

Research output: Contribution to journalArticle

496 Citations (Scopus)

Abstract

Leukemic cells from 30% of patients with acute myeloid leukemia (AML) have an activating mutation in the FLT3 (fms-like tyrosine kinase) gene, which represents a target for drug therapy. We treated 20 patients, each with mutant FLT3 relapsed/refractory AML or high-grade myelodysplastic syndrome and not believed to be candidates for chemotherapy, with an FLT3 tyrosine kinase inhibitor, PKC412 (N-benzoylstaurosporine), at a dose of 75 mg 3 times daily by mouth. The drug was generally well tolerated, although 2 patients developed fatal pulmonary events of unclear etiology. The peripheral blast count decreased by 50% in 14 patients (70%). Seven patients (35%) experienced a greater than 2-log reduction in peripheral blast count for at least 4 weeks (median response duration, 13 weeks; range, 9-47 weeks); PKC412 reduced bone marrow blast counts by 50% in 6 patients (2 of these to < 5%). FLT3 autophosphorylation was inhibited in most of the responding patients, indicating in vivo target inhibition at the dose schedule used in this study. PKC412 is an oral tyrosine kinase inhibitor with clinical activity in patients with AML whose blasts have an activating mutation of FLT3, suggesting potential use in combination with active agents, such as chemotherapy.

Original languageEnglish
Pages (from-to)54-60
Number of pages7
JournalBlood
Volume105
Issue number1
DOIs
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

4'-N-benzoylstaurosporine
Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Mutation
Molecules
Chemotherapy
Vascular Endothelial Growth Factor Receptor-1
Drug therapy
Drug Therapy
Refractory materials
Bone
Genes
Myelodysplastic Syndromes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology

Cite this

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. / Stone, Richard M.; DeAngelo, Daniel J.; Klimek, Virginia; Galinsky, Ilene; Estey, Eli; Nimer, Stephen D; Grandin, Wilson; Lebwohl, David; Wang, Yanfeng; Cohen, Pamela; Fox, Edward A.; Neuberg, Donna; Clark, Jennifer; Gilliland, D. Gary; Griffin, James D.

In: Blood, Vol. 105, No. 1, 01.01.2005, p. 54-60.

Research output: Contribution to journalArticle

Stone, RM, DeAngelo, DJ, Klimek, V, Galinsky, I, Estey, E, Nimer, SD, Grandin, W, Lebwohl, D, Wang, Y, Cohen, P, Fox, EA, Neuberg, D, Clark, J, Gilliland, DG & Griffin, JD 2005, 'Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412', Blood, vol. 105, no. 1, pp. 54-60. https://doi.org/10.1182/blood-2004-03-0891
Stone, Richard M. ; DeAngelo, Daniel J. ; Klimek, Virginia ; Galinsky, Ilene ; Estey, Eli ; Nimer, Stephen D ; Grandin, Wilson ; Lebwohl, David ; Wang, Yanfeng ; Cohen, Pamela ; Fox, Edward A. ; Neuberg, Donna ; Clark, Jennifer ; Gilliland, D. Gary ; Griffin, James D. / Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. In: Blood. 2005 ; Vol. 105, No. 1. pp. 54-60.
@article{74f4fc36a56f43a69c4130cfe036cc4b,
title = "Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412",
abstract = "Leukemic cells from 30{\%} of patients with acute myeloid leukemia (AML) have an activating mutation in the FLT3 (fms-like tyrosine kinase) gene, which represents a target for drug therapy. We treated 20 patients, each with mutant FLT3 relapsed/refractory AML or high-grade myelodysplastic syndrome and not believed to be candidates for chemotherapy, with an FLT3 tyrosine kinase inhibitor, PKC412 (N-benzoylstaurosporine), at a dose of 75 mg 3 times daily by mouth. The drug was generally well tolerated, although 2 patients developed fatal pulmonary events of unclear etiology. The peripheral blast count decreased by 50{\%} in 14 patients (70{\%}). Seven patients (35{\%}) experienced a greater than 2-log reduction in peripheral blast count for at least 4 weeks (median response duration, 13 weeks; range, 9-47 weeks); PKC412 reduced bone marrow blast counts by 50{\%} in 6 patients (2 of these to < 5{\%}). FLT3 autophosphorylation was inhibited in most of the responding patients, indicating in vivo target inhibition at the dose schedule used in this study. PKC412 is an oral tyrosine kinase inhibitor with clinical activity in patients with AML whose blasts have an activating mutation of FLT3, suggesting potential use in combination with active agents, such as chemotherapy.",
author = "Stone, {Richard M.} and DeAngelo, {Daniel J.} and Virginia Klimek and Ilene Galinsky and Eli Estey and Nimer, {Stephen D} and Wilson Grandin and David Lebwohl and Yanfeng Wang and Pamela Cohen and Fox, {Edward A.} and Donna Neuberg and Jennifer Clark and Gilliland, {D. Gary} and Griffin, {James D.}",
year = "2005",
month = "1",
day = "1",
doi = "10.1182/blood-2004-03-0891",
language = "English",
volume = "105",
pages = "54--60",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412

AU - Stone, Richard M.

AU - DeAngelo, Daniel J.

AU - Klimek, Virginia

AU - Galinsky, Ilene

AU - Estey, Eli

AU - Nimer, Stephen D

AU - Grandin, Wilson

AU - Lebwohl, David

AU - Wang, Yanfeng

AU - Cohen, Pamela

AU - Fox, Edward A.

AU - Neuberg, Donna

AU - Clark, Jennifer

AU - Gilliland, D. Gary

AU - Griffin, James D.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Leukemic cells from 30% of patients with acute myeloid leukemia (AML) have an activating mutation in the FLT3 (fms-like tyrosine kinase) gene, which represents a target for drug therapy. We treated 20 patients, each with mutant FLT3 relapsed/refractory AML or high-grade myelodysplastic syndrome and not believed to be candidates for chemotherapy, with an FLT3 tyrosine kinase inhibitor, PKC412 (N-benzoylstaurosporine), at a dose of 75 mg 3 times daily by mouth. The drug was generally well tolerated, although 2 patients developed fatal pulmonary events of unclear etiology. The peripheral blast count decreased by 50% in 14 patients (70%). Seven patients (35%) experienced a greater than 2-log reduction in peripheral blast count for at least 4 weeks (median response duration, 13 weeks; range, 9-47 weeks); PKC412 reduced bone marrow blast counts by 50% in 6 patients (2 of these to < 5%). FLT3 autophosphorylation was inhibited in most of the responding patients, indicating in vivo target inhibition at the dose schedule used in this study. PKC412 is an oral tyrosine kinase inhibitor with clinical activity in patients with AML whose blasts have an activating mutation of FLT3, suggesting potential use in combination with active agents, such as chemotherapy.

AB - Leukemic cells from 30% of patients with acute myeloid leukemia (AML) have an activating mutation in the FLT3 (fms-like tyrosine kinase) gene, which represents a target for drug therapy. We treated 20 patients, each with mutant FLT3 relapsed/refractory AML or high-grade myelodysplastic syndrome and not believed to be candidates for chemotherapy, with an FLT3 tyrosine kinase inhibitor, PKC412 (N-benzoylstaurosporine), at a dose of 75 mg 3 times daily by mouth. The drug was generally well tolerated, although 2 patients developed fatal pulmonary events of unclear etiology. The peripheral blast count decreased by 50% in 14 patients (70%). Seven patients (35%) experienced a greater than 2-log reduction in peripheral blast count for at least 4 weeks (median response duration, 13 weeks; range, 9-47 weeks); PKC412 reduced bone marrow blast counts by 50% in 6 patients (2 of these to < 5%). FLT3 autophosphorylation was inhibited in most of the responding patients, indicating in vivo target inhibition at the dose schedule used in this study. PKC412 is an oral tyrosine kinase inhibitor with clinical activity in patients with AML whose blasts have an activating mutation of FLT3, suggesting potential use in combination with active agents, such as chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=19944427559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944427559&partnerID=8YFLogxK

U2 - 10.1182/blood-2004-03-0891

DO - 10.1182/blood-2004-03-0891

M3 - Article

C2 - 15345597

AN - SCOPUS:19944427559

VL - 105

SP - 54

EP - 60

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -